Related Experiment Video
Updated: Jun 15, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
[Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B]
Xiaoyan Wang1, Shourong Shen, Nan Li
1Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objective:
To evaluate the therapeutic effect of Ursodeoxycholi acid on the treatment of liver cirrhosis with hepatitis B.
Methods:
Eighty-four patients with liver cirrhosis were randomly divided into 2 groups:42 to the treatment group who were given oral capsules of Ursodeoxycholi acid combined with reduced glutathione,and the other 42 to the control group who received Yinzhihuang intravenously, combined with reduced glutathione. Therapeutic efficacy,liver function and its normalization rate,and score of Child-pugh-Turcotte (CPT)were observed after 4 week treatment and 8 week treatment.
Results:
The therapeutic efficacy had no significant difference between the treatment group and the control group (P>0.05). Compared with the control group, the values of gamma-glutamyl transpeptidase (gamma-GT), alkaline phosphatase (AKP) and globulin(GLO) of the treatment group decreased more significantly (P<0.05), and the normalization rates of gamma-GT and AKP in the treatment group was significantly higher than that in the control group at 8 week. The decreased levels of total bilirubin (TBIL) and direct bilirubin(DBIL) were not significantly different between the 2 groups (P>0.05). At 4 week the decrease level of ALT in the 2 groups was similar (P>0.05), while at 8 week the values of ALT reduced more significantly than that of the control group(P<0.05). The score of CPT of the 2 groups were not different after 4 week and 8 week treatment (P>0.05).
Conclusion:
Ursodeoxycholi acid can obviously decrease the values of gamma-GT, AKP and GLO in liver cirrhosis with hepatitis B, which may be related to Ursodeoxycholi acid relieving the injury of bile duct and enhancing biliary transport.
Related Concept Videos
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatitis